Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Atorvastatin Calcium

FDA-approved product (tablet, oral), marketed as Atorvaliq, Atorvastatin Calcium, Lipitor.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Atorvastatin Calcium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Abnormal circulating lipid concentration
  • Acute myocardial infarction
  • Angina pectoris
  • Cardiovascular disease
  • Congestive heart failure
  • Coronary artery disease
  • Familial hypercholesterolemia
  • Heart failure
  • Hypercholesterolemia
  • Hyperlipidemia
  • Hypertension
  • Myocardial infarction
  • Stroke

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Hmg coa reductase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA41.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli25.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae15.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Atorvastatin Calcium in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Atorvastatin Calcium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Evaluate the Efficacy and Safety of KI1106 in Patients Whose TG Level is Not Adequately Controlled With Atorvastatin Calcium Monotherapy While LDL-C is Properly Controlled

    NCT03482180 · start 2016-05-04

    Registered record
    Registry ID
    NCT03482180
    Conditions
    Dyslipidemias
    Interventions
    KI1106 4g, QD; Atorvastatin Calcium 20mg, QD
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-05-04
    Completion
    2018-03-23
    Enrolment
    215

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDyslipidemias
    InterventionKI1106 4g, QD; Atorvastatin Calcium 20mg, QD
    PhasePhase 3
    Registry statusCompleted

  • Study of the Effect of Atorvastatin for Reducing Aging-related Complication in HIV-infected Patients Older Than 45 Years Receiving a Protease Inhibitor-based Regimen Versus a Raltegravir-based Regimen

    NCT02577042 · start 2015-10-15

    Registered record
    Registry ID
    NCT02577042
    Conditions
    Aging-related Inflammation in HIV-infected Patients
    Interventions
    Raltegravir; PI-based regimen; Atorvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-10-15
    Completion
    2018-06-04
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAging-related Inflammation in HIV-infected Patients
    InterventionRaltegravir; PI-based regimen; Atorvastatin
    PhasePhase 4
    Registry statusCompleted

  • Renal Artery Stenting in Patients With Documented Resistant Hypertension and Atherosclerotic Renal Artery Stenosis (ANDORRA)

    NCT02539810 · start 2015-09

    Registered record
    Registry ID
    NCT02539810
    Conditions
    Hypertension; Hypertension Resistant to Conventional Therapy; Angiographically Proven Grade III Unilateral or Bilateral Atherosclerotic Renal Artery Stenosis (ARAS) Greater Than or Equal to 60 Percent
    Interventions
    Renal artery Angioplasty plus stenting.; Anti hypertensive, statin and antiplatelet medication.
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2015-09
    Completion
    2017-07
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Hypertension Resistant to Conventional Therapy; Angiographically Proven Grade III Unilateral or Bilateral Atherosclerotic Renal Artery Stenosis (ARAS) Greater Than or Equal to 60 Percent
    InterventionRenal artery Angioplasty plus stenting.; Anti hypertensive, statin and antiplatelet medication.
    PhasePhase 4
    Registry statusTerminated

  • Atorvastatin in Active Vitiligo

    NCT02432534 · start 2015-05

    Registered record
    Registry ID
    NCT02432534
    Conditions
    Vitiligo
    Interventions
    Atorvastatin; UVB
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-05
    Completion
    2017-12
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVitiligo
    InterventionAtorvastatin; UVB
    PhasePhase 2
    Registry statusCompleted

  • Atorvastatin Study in Cardiovascular Disease Risk

    NCT02392416 · start 2015-04

    Registered record
    Registry ID
    NCT02392416
    Conditions
    Hypercholesterolemia; Dyslipidemia
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-04
    Completion
    2016-02
    Enrolment
    900

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypercholesterolemia; Dyslipidemia
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Interest of COLchicine in the Treatment of Patients With Acute Myocardial INfarction and With Inflammatory Response

    NCT02363725 · start 2014-12

    Registered record
    Registry ID
    NCT02363725
    Conditions
    Acute Myocardial Infarction
    Interventions
    Colchimax®; Conventional treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-12
    Completion
    2016-08
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myocardial Infarction
    InterventionColchimax®; Conventional treatment
    PhasePhase 2
    Registry statusCompleted

  • Aggressive Cholesterol Therapy to Inhibit Vein Graft Events After CABG (ACTIVE Trial)

    NCT01528709 · start 2012-03

    Registered record
    Registry ID
    NCT01528709
    Conditions
    Saphenous Vein Graft Disease
    Interventions
    Atorvastatin 80 mg daily; Atorvastatin 10 mg daily
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-03
    Completion
    2017-01
    Enrolment
    173

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSaphenous Vein Graft Disease
    InterventionAtorvastatin 80 mg daily; Atorvastatin 10 mg daily
    PhasePhase 3
    Registry statusCompleted

  • Effects of Atorvastatin Treatment on Left Ventricular Diastolic Function in Peritoneal Dialysis Patients

    NCT01503671 · start 2011-11

    Registered record
    Registry ID
    NCT01503671
    Conditions
    Heart Failure
    Interventions
    Atorvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2011-11
    Completion
    2015-10
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure
    InterventionAtorvastatin
    PhasePhase 4
    Registry statusUnknown

  • Can Atorvastatin Improve Vascular Function in Women With a History of Preeclampsia?

    NCT01278459 · start 2011-10

    Registered record
    Registry ID
    NCT01278459
    Conditions
    Pre-Eclampsia
    Interventions
    Atorvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-10
    Completion
    2012-04
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPre-Eclampsia
    InterventionAtorvastatin
    PhasePhase 3
    Registry statusCompleted

  • Diabetic Treatment Adherence

    NCT01318564 · start 2011-03

    Registered record
    Registry ID
    NCT01318564
    Conditions
    Endocrine System Diseases
    Interventions
    Metformin; Questionnaires
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2011-03
    Completion
    2016-08
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndocrine System Diseases
    InterventionMetformin; Questionnaires
    PhaseNot recorded
    Registry statusCompleted

  • Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With High Dose of Atorvastatin in Patients With Primary Hypercholesterolemia

    NCT01288469 · start 2011-01

    Registered record
    Registry ID
    NCT01288469
    Conditions
    Hypercholesterolemia
    Interventions
    Alirocumab; Placebo (for alirocumab); Atorvastatin; Placebo (for atorvastatin)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-01
    Completion
    2011-09
    Enrolment
    92

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypercholesterolemia
    InterventionAlirocumab; Placebo (for alirocumab); Atorvastatin; Placebo (for atorvastatin)
    PhasePhase 2
    Registry statusCompleted

  • Statins in Children With Type 1 Diabetes and Hypercholesterolemia

    NCT01236365 · start 2010-10

    Registered record
    Registry ID
    NCT01236365
    Conditions
    Diabetes Mellitus, Insulin-Dependent; Hypercholesterolemia
    Interventions
    Atorvastatin; Atorvastatin Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-10
    Completion
    2014-11
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Insulin-Dependent; Hypercholesterolemia
    InterventionAtorvastatin; Atorvastatin Placebo
    PhasePhase 3
    Registry statusCompleted

  • Open Label Study To Evaluate The Long-Term Safety Profiles Of Caduet In Japanese Patients

    NCT01190007 · start 2010-08

    Registered record
    Registry ID
    NCT01190007
    Conditions
    Hypertension; Hypercholesterolemia; Angina Pectoris
    Interventions
    Caduet
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-08
    Completion
    2012-02
    Enrolment
    159

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Hypercholesterolemia; Angina Pectoris
    InterventionCaduet
    PhasePhase 4
    Registry statusCompleted

  • Intensive Statin Treatment in Chinese Coronary Artery Disease Patients Undergoing PCI

    NCT01293097 · start 2010-06

    Registered record
    Registry ID
    NCT01293097
    Conditions
    Non-ST Segment Elevation Myocardial Infarction; Unstable Angina Pectoris; Stable Angina Pectoris
    Interventions
    Atorvastatin; Statin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-06
    Completion
    2011-10
    Enrolment
    2,884

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-ST Segment Elevation Myocardial Infarction; Unstable Angina Pectoris; Stable Angina Pectoris
    InterventionAtorvastatin; Statin
    PhasePhase 4
    Registry statusCompleted

  • Rosuvastatin for Reduction of Myocardial Damage and Systemic Inflammation During Coronary Angioplasty

    NCT02205775 · start 2010-05

    Registered record
    Registry ID
    NCT02205775
    Conditions
    Stable Coronary Artery Disease Undergoing PCI
    Interventions
    Atorvastatin; Rosuvastatin; Rosuvastatin; Ezetimibe; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2010-05
    Completion
    2012-06
    Enrolment
    280

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStable Coronary Artery Disease Undergoing PCI
    InterventionAtorvastatin; Rosuvastatin; Rosuvastatin; Ezetimibe +1 more
    PhasePhase 3
    Registry statusTerminated